Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children's nutritionals business. In June 2008, BMS acquired Kosan Biosciences, Inc., a developer of oncology products. In August 2008, the Company completed the divestiture of its ConvaTec business to Cidron Healthcare Limited, an affiliate of Nordic Capital Fund VII and Avista. In December 2008, BMS completed the sale of its brand business in Egypt to GlaxoSmithKline. In July 2009, the Company's branded generics business, which comprises a portfolio of 13 branded pharmaceuticals was acquired by GlaxoSmithKline pl
Bristol Myers Squibb Co.
NYSE:BMY ISIN:US1101221083
News
Japan's Taisho Pharmaceutical Co. Ltd. (TYO:4535) said Wednesday it will buy Bristol-Myers Squibb Co.'s (NYSE:BMY) over-the-counter drug assets worth US$310 million in Asia Pacific (excluding China and Japan).
###
19,049 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 8) (Last 30 Days: 45) (Since Published: 4605)